Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THEOLAIR-SR vs AEROLONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing c AMP, and antagonizing adenosine receptors.
Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.
Treatment of symptoms and prevention of asthma,Treatment of chronic bronchitis and emphysema (COPD),Apnea of prematurity (off-label)
Treatment of bronchospasm in patients with COPD,Long-term maintenance treatment of asthma
Oral: 300-600 mg every 12 hours; sustained-release formulation; adjust based on serum theophylline concentrations (target 5-15 mcg/m L).
AEROLONE is not a recognized drug; no standard dosing available.
Adults: 8 hours (range 5-12). Children: 3.5 hours (range 1-8). Smokers: 4-5 hours. Congestive heart failure/hepatic cirrhosis: >24 hours.
Terminal elimination half-life is approximately 12-15 hours in adults; prolonged to 24-30 hours in severe renal impairment (Cr Cl <30 m L/min).
Primarily metabolized by hepatic CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Extensive first-pass metabolism. Metabolites excreted renally.
Primarily metabolized by CYP3A4 and to a lesser extent CYP2D6, with conjugation to inactive metabolites.
Renal (10% unchanged) and hepatic metabolism (90%). Metabolites excreted in urine.
Primarily renal excretion of unchanged drug (approximately 65%) and hepatic metabolism (35%), with metabolites excreted in urine and feces. Biliary/fecal elimination accounts for <10%.
40% bound, primarily to albumin.
Approximately 88% bound, primarily to albumin and alpha-1-acid glycoprotein.
0.45 L/kg. Distributes into total body water; higher in premature infants and patients with cirrhosis.
3.5-5.0 L/kg, indicating extensive extravascular distribution and tissue binding.
Oral (extended-release): 96-100%.
Oral: 35-50% (first-pass metabolism); Inhalation: 15-30% (dependent on device and technique); Intravenous: 100%.
No specific GFR-based dose adjustment required; use with caution in renal impairment due to altered clearance; monitor serum concentrations.
No data; not applicable.
Child-Pugh Class A: Reduce dose by 50%. Child-Pugh Class B: Reduce dose by 50% and monitor closely. Child-Pugh Class C: Consider alternative therapy; if used, reduce dose by 75% with frequent monitoring.
No data; not applicable.
Children >1 year: Initial 16 mg/kg/day or 400 mg/day (whichever is less) divided every 12 hours; maximum dose: 24 mg/kg/day (not to exceed 900 mg/day). Target serum concentration 5-15 mcg/m L.
No data; not applicable.
Over 60 years: Lower initial dose (e.g., 300 mg/day) due to decreased clearance; titrate slowly; monitor serum theophylline concentrations closely to avoid toxicity.
No data; not applicable.
Theophylline has a narrow therapeutic index; serum levels must be monitored to avoid toxicity. Dose-related adverse effects include seizures and arrhythmias.
None
Risk of seizure and arrhythmia at toxic levels; monitor serum theophylline concentrations closely. Use with caution in patients with heart failure, hepatic impairment, chronic alcoholism, and viral infections. Interactions with drugs affecting CYP1A2 (e.g., ciprofloxacin, fluvoxamine, smoking cessation) require dose adjustment.
Paradoxical bronchospasm,Cardiovascular effects (e.g., increased heart rate, QT prolongation),Hypokalemia,Hyperglycemia
Hypersensitivity to theophylline or any component of the formulation. Patients with pre-existing cardiac arrhythmias (e.g., atrial fibrillation, ventricular tachycardia) unless controlled. History of seizure disorder (use only if benefits outweigh risks).
Hypersensitivity to arformoterol or any component of the formulation
High-fat meals may increase absorption; avoid drastic dietary changes. Concurrent caffeine intake can increase theophylline effects and toxicity risk. Charcoal-broiled foods and a high-protein diet may decrease theophylline levels. Grapefruit juice may increase theophylline levels (moderate interaction).
No significant food interactions. Avoid grapefruit juice as it may affect metabolism of the corticosteroid component.
Theophylline crosses the placenta. First trimester: No clear evidence of major malformations in human studies, but animal studies show some risk at high doses (skeletal variations). Second trimester: No specific risks; use if benefit outweighs risk. Third trimester: Fetal tachycardia, jitteriness, and withdrawal symptoms (irritability, vomiting) in neonates due to transplacental accumulation. Avoid near term if possible.
No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled studies exist; however, data from postmarketing reports do not suggest an increased risk of structural anomalies. First trimester: limited data preclude definitive risk assessment, but no pattern of major birth defects has emerged. Second and third trimesters: no known fetal harm from inhaled doses; however, potential for fetal adrenal suppression with prolonged high-dose systemic exposure.
Theophylline is excreted into breast milk. Milk/plasma ratio approximately 0.6-0.7. Infant exposure is about 1-10% of maternal weight-adjusted dose, leading to potentially therapeutic or toxic levels in infant serum. Possible effects include irritability, insomnia, and feeding intolerance. Use with caution; monitor infant for adverse effects.
Unknown whether fluticasone propionate is excreted in human breast milk. Other corticosteroids are excreted in breast milk in low amounts, and inhaled doses result in negligible systemic levels, predicting unlikely significant infant exposure. M/P ratio not determined. Caution advised; weigh risk of maternal obstructive airway disease exacerbation against potential infant risks (adrenal suppression, growth retardation).
Significant pharmacokinetic changes: increased clearance due to hepatic induction and increased renal excretion; decreased protein binding. May require dose increase. Monitor serum concentrations frequently (every 2-4 weeks) and adjust to maintain therapeutic levels (5-15 mcg/m L). Postpartum, clearance decreases; reduce dose to prevent toxicity.
No specific dose adjustment required based on pharmacokinetic changes; pregnancy may cause decreased airway reactivity but no significant changes in fluticasone clearance. Maintain lowest effective dose to control asthma. No dose increase recommended solely due to pregnancy. Monitor asthma control and adjust dose as per standard guidelines.
Theolair-SR is a sustained-release theophylline formulation. Monitor serum theophylline levels (therapeutic range 10-20 mcg/m L) to avoid toxicity, especially in patients with hepatic impairment or those on interacting drugs. Tachyphylaxis may occur with chronic use. Caution in patients with peptic ulcer, seizure disorders, or cardiac arrhythmias. Levels may be affected by smoking cessation, fever, or medications like cimetidine, fluoroquinolones, and macrolides.
AEROLONE is a combination inhaler containing an inhaled corticosteroid (fluticasone propionate) and a long-acting beta2-agonist (salmeterol). Advise patients to rinse mouth with water after each use to reduce risk of oral candidiasis. Not for acute bronchospasm; use a rescue inhaler (short-acting beta agonist) as needed. Monitor for increased heart rate, palpitations, or tremor. Do not stop abruptly; taper dose under medical supervision if discontinuing.
Take this medication exactly as prescribed; do not crush or chew the sustained-release tablets.,Avoid taking with large amounts of caffeine (coffee, tea, soda) as it may increase side effects.,Report symptoms of toxicity: nausea, vomiting, restlessness, insomnia, rapid heartbeat, or seizures.,Do not change brands or dosing schedule without consulting your provider.,Maintain consistent intake of food and avoid sudden changes in diet that may affect absorption.
Use AEROLONE exactly as prescribed; do not exceed recommended dose.,Rinse your mouth with water after each use (do not swallow) to prevent thrush.,This medication is not for sudden breathing problems; always keep your rescue inhaler (e.g., albuterol) with you.,Do not stop using this medicine without talking to your doctor, as stopping suddenly may worsen your breathing.,Seek immediate medical help if you experience worsening asthma, chest pain, or allergic reaction.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THEOLAIR-SR vs AEROLONE, answered by our medical review team.
THEOLAIR-SR is a Bronchodilator that works by Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing c AMP, and antagonizing adenosine receptors.. AEROLONE is a Bronchodilator that works by Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THEOLAIR-SR and AEROLONE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THEOLAIR-SR is: Oral: 300-600 mg every 12 hours; sustained-release formulation; adjust based on serum theophylline concentrations (target 5-15 mcg/m L).. The standard adult dose of AEROLONE is: AEROLONE is not a recognized drug; no standard dosing available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THEOLAIR-SR and AEROLONE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THEOLAIR-SR is classified as Category C. Theophylline crosses the placenta. First trimester: No clear evidence of major malformations in human studies, but animal studies show some risk at high doses (skeletal variations). AEROLONE is classified as Category C. No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled stu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.